Roy El Darzi· @Royeldarzi · X·· 11 小时前评分70
正文 · 机器翻译
DeLLphi-305 在 #ESMO26 公布的结果令人鼓舞！
Tarlatamab + durvalumab 维持治疗将广泛期 SCLC 的中位 OS 从 12.7 个月提升至 21.1 个月。
对于这一治疗选择有限的疾病而言，这是令人振奋的一步！ #LungCancer
26 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgPresented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: https://nej.md/4iveIgW @myESMO在 X 查看被引用的帖子
来源：Roy El Darzi · x.com